Dimerix

Dimerix R&D / Revenue

The R&D to Revenue Ratio of Dimerix (DXB.AX) as of Oct 19, 2026 is 828.15 %. In the previous year, R&D to Revenue Ratio was 2,177.88 % — a change of -61.97% (lower).

R&D / Revenue

828.15 %

YoY

-61.97%

Last updated:

R&D to Revenue Ratio of Dimerix is 2026 828.15 % . R&D to Revenue Ratio of Dimerix was 2025 2,177.88 % . It decreases by -61.97% lower compared to the previous year.

The Dimerix R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2019
196.06 AUD
Jan 1, 2020
236.57 AUD
Jan 1, 2021
210.18 AUD
Jan 1, 2022
222.64 AUD
Jan 1, 2023
55,655.53 AUD
Jan 1, 2024
3,615.90 AUD
Jan 1, 2025
2,177.88 AUD
Jan 1, 2026
828.15 AUD
The Dimerix R&D / Revenue history
YEARR&D / RevenueYoY
828.15 %-61.97%
2,177.88 %-39.77%
3,615.90 %-93.50%
55,655.53 %+24,898.38%
222.64 %+5.93%
210.18 %-11.15%
236.57 %+20.66%
196.06 %-19.20%
242.64 %+53.25%
158.33 %+64.03%
96.53 %+8.54%
88.93 %+43.05%
62.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

R&D to Revenue Ratio of Dimerix is 828.15 % in 2026.

R&D to Revenue Ratio of Dimerix changed from 2,177.88 % to 828.15 %, representing a -61.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Dimerix since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Dimerix with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Dimerix

All Key Metrics — Dimerix